Is there a disease-modifying effect of long-term cyclic iloprost therapy in systemic sclerosis?

被引：0
|
作者：
Airo, P. [1 ]
Scarsi, M. [1 ]
Danieli, E. [1 ]
Rossi, M. [1 ]
Grotto, A. [1 ]
Zambruni, A. [1 ]
机构：
[1] Spedali Civil Brescia, Syst Autoimmune Dis Unit, I-25125 Brescia, Italy
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2007年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：197 / 197
页数：1
相关论文
共 50 条
  • [1] Disease-modifying effects of long-term cyclic iloprost therapy in systemic sclerosis.: A retrospective analysis and comparison with a control group
    Airo, P.
    Rossi, M.
    Scarsi, A.
    Danieli, E.
    Grottolo, A.
    Zambruni, A.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2007, 25 (05) : 722 - 727
  • [2] Long-term effects of cyclic therapy with iloprost in systemic sclerosis
    Scarsi, M.
    Rossi, M.
    Danieli, E.
    Frige, A.
    Grottolo, A.
    Zambruni, A.
    Airo, P.
    [J]. REUMATISMO, 2008, 60 (02) : 114 - 119
  • [3] DISEASE-MODIFYING EFFECT OF ILOPROST THERAPY IN SYSTEMIC SCLERODERMA
    Yatsyshyn, R.
    Yatsyshyn, M.
    [J]. RHEUMATOLOGY, 2012, 51 : 48 - 48
  • [4] Long-term effect of delaying disease-modifying therapy in patients with multiple sclerosis due to pregnancy planning
    Makkawi, Seraj
    Lavorato, Dina
    Greenfield, Jamie
    Parpal, Helene
    Metz, Luanne
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) : NP14 - NP14
  • [5] Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis
    Stuart, WH
    Cohan, S
    Richert, JR
    Achiron, A
    [J]. NEUROLOGY, 2004, 63 (11) : S19 - S27
  • [6] Estimating long-term effects of disease-modifying drug, therapy in multiple sclerosis patients
    Rudick, RA
    Cutter, GR
    Baier, M
    Weinstock-Guttman, B
    Mass, MK
    Fisher, E
    Miller, DM
    Sandrock, AW
    [J]. MULTIPLE SCLEROSIS, 2005, 11 (06): : 626 - 634
  • [7] Emerging targets of disease-modifying therapy for systemic sclerosis
    Elizabeth R. Volkmann
    John Varga
    [J]. Nature Reviews Rheumatology, 2019, 15 : 208 - 224
  • [8] The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis
    Claflin, Suzi B.
    Campbell, Julie A.
    Mason, Deborah F.
    Kalincik, Tomas
    Simpson-Yap, Steve
    Norman, Richard
    Butzkueven, Helmut
    Carroll, William M.
    Palmer, Andrew J.
    Blizzard, C. Leigh
    van der Mei, Ingrid
    Taylor, Bruce, V
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (05) : 831 - 841
  • [9] Emerging targets of disease-modifying therapy for systemic sclerosis
    Volkmann, Elizabeth R.
    Varga, John
    [J]. NATURE REVIEWS RHEUMATOLOGY, 2019, 15 (04) : 208 - 224
  • [10] Comparative effectiveness of long-term users of disease-modifying therapy
    Salter, A.
    Tang, Y.
    Hornung, L.
    Kolodny, S.
    Hurtukova, D.
    Glenski, S.
    Cofield, S.
    Zhang, X.
    Cutter, G.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 309 - 310
12345